Cardiovascular MRI with ferumoxytol

Area of Science:

• Radiology
• Nanotechnology
• Cardiovascular Imaging

Background:

• Contrast-enhanced magnetic resonance angiography (CEMRA) practices have evolved due to safety concerns with gadolinium (Gd)-based contrast agents, particularly nephrogenic systemic fibrosis in renal impairment.
• This has driven the development of low-dose CEMRA, non-contrast MRA, and alternative contrast agents.
• Ferumoxytol, an ultra-small superparamagnetic iron oxide nanoparticle, is FDA-approved for anemia in renal disease and has gained interest as an MRI contrast agent.

Purpose of the Study:

• To summarize cardiovascular applications and ongoing investigations of ferumoxytol as a magnetic resonance imaging (MRI) contrast agent.
• To highlight ferumoxytol's potential as a game-changer in CEMRA and MRI.

Main Methods:

• Review of clinical experience with cardiovascular applications of ferumoxytol.
• Synopsis of ongoing research into ferumoxytol-enhanced MR applications.

Main Results:

• Ferumoxytol possesses unique physicochemical and pharmacokinetic properties, including a long intravascular half-life and high r1 relaxivity.
• These properties support a broad range of MRI applications, potentially exceeding those of Gd-based agents.
• Iron, unlike Gd, is essential for human metabolism, and ferumoxytol's iron core is incorporated into the reticuloendothelial system after degradation.

Conclusions:

• Ferumoxytol's safety profile and biological relevance position it as a significant advancement in CEMRA and MRI.
• Its potential extends beyond current Gd-based contrast agent applications.
• Further research into ferumoxytol-enhanced MR applications is warranted.